Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer

Author(s): Jun Watanabe, MD, PhD¹; Kei Muro, MD, PhD²; Kohei Shitara, MD, PhD^3,4; Kentaro Yamazaki, MD, PhD⁵; Manabu Shiozawa, MD, PhD⁶; Hisatsugu Ohori, MD, PhD⁷; Atsuo Takashima, MD, PhD⁸; Mitsuru Yokota, MD, PhD⁹; Akitaka Makiyama, MD, PhD¹⁰; Naoya Akazawa, MD¹¹; Hitoshi Ojima, MD, PhD¹²; Yasuhiro Yuasa, MD, PhD¹³; Keisuke Miwa, MD, PhD¹⁴; Hirofumi Yasui, MD, PhD⁵; Eiji Oki, MD, PhD¹⁵; Takeo Sato, MD, PhD¹⁶; Takeshi Naitoh, MD, PhD¹⁷; Yoshito Komatsu, MD, PhD¹⁸; Takeshi Kato, MD, PhD¹⁹; Masamitsu Hihara, MS²⁰; Junpei Soeda, MD, PhD²⁰; Toshihiro Misumi, PhD²¹; Kouji Yamamoto, PhD²¹; Kiwamu Akagi, MD, PhD²²; Atsushi Ochiai, MD, PhD^23,24; Hiroyuki Uetake, MD, PhD²⁵; Katsuya Tsuchihara, MD, PhD²⁶; Takayuki Yoshino, MD, PhD³

Source: JAMA. 2023;329(15):1271-1282. doi:10.1001/jama.2023.4428

Dr. Maen Hussein's Thoughts

In this study, Cetuximab beat Bevacizumab in left sided KRAS wild type colon cancer.

IMPORTANCE

For patients with RAS wild-type metastatic colorectal cancer, adding anti–epidermal growth factor receptor (anti-EGFR) or anti–vascular endothelial growth factor (anti-VEGF) monoclonal antibodies to first-line doublet chemotherapy is routine, but the optimal targeted therapy has not been defined.

OBJECTIVE

To evaluate the effect of adding panitumumab (an anti-EGFR monoclonal antibody) vs bevacizumab (an anti-VEGF monoclonal antibody) to standard first-line chemotherapy for treatment of RAS wild-type, left-sided, metastatic colorectal cancer.

DESIGN, SETTING, AND PARTICIPANT

Randomized, open-label, phase 3 clinical trial at 197 sites in Japan in May 2015–January 2022 among 823 patients with chemotherapy-naive RAS wild-type, unresectable metastatic colorectal cancer (final follow-up, January 14, 2022).

INTERVENTIONS

Panitumumab (n = 411) or bevacizumab (n = 412) plus modified fluorouracil, l-leucovorin, and oxaliplatin (mFOLFOX6) every 14 days.

MAIN OUTCOMES AND MEASURES

The primary end point, overall survival, was tested first in participants with left-sided tumors, then in the overall population. Secondary end points were progression-free survival, response rate, duration of response, and curative (defined as R0 status) resection rate.

RESULTS

In the as-treated population (n = 802; median age, 66 years; 282 [35.2%] women), 604 (75.3%) had left-sided tumors. Median follow-up was 61 months. Median overall survival was 37.9 months with panitumumab vs 34.3 months with bevacizumab in participants with left-sided tumors (hazard ratio [HR] for death, 0.82; 95.798% CI, 0.68-0.99; P = .03) and 36.2 vs 31.3 months, respectively, in the overall population (HR, 0.84; 95% CI, 0.72-0.98; P = .03). Median progression-free survival for panitumumab vs bevacizumab was 13.1 vs 11.9 months, respectively, for those with left-sided tumors (HR, 1.00; 95% CI, 0.83-1.20) and 12.2 vs 11.4 months overall (HR, 1.05; 95% CI, 0.90-1.24). Response rates with panitumumab vs bevacizumab were 80.2% vs 68.6%, respectively, for left-sided tumors (difference, 11.2%; 95% CI, 4.4%-17.9%) and 74.9% vs 67.3% overall (difference, 7.7%; 95% CI, 1.5%-13.8%). Median duration of response with panitumumab vs bevacizumab was 13.1 vs 11.2 months for left-sided tumors (HR, 0.86; 95% CI, 0.70-1.10) and 11.9 vs 10.7 months overall (HR, 0.89; 95% CI, 0.74-1.06). Curative resection rates with panitumumab vs bevacizumab were 18.3% vs 11.6% for left-sided tumors; (difference, 6.6%; 95% CI, 1.0%-12.3%) and 16.5% vs 10.9% overall (difference, 5.6%; 95% CI, 1.0%-10.3%). Common treatment-emergent adverse events were acneiform rash (panitumumab: 74.8%; bevacizumab: 3.2%), peripheral sensory neuropathy (panitumumab: 70.8%; bevacizumab: 73.7%), and stomatitis (panitumumab: 61.6%; bevacizumab: 40.5%).

CONCLUSIONS AND RELEVANCE

Among patients with RAS wild-type metastatic colorectal cancer, adding panitumumab, compared with bevacizumab, to standard first-line chemotherapy significantly improved overall survival in those with left-sided tumors and in the overall population.

Author Affiliations

¹Department of Surgery, Gastroenterological Center, Yokohama City University Medical Center, Yokohama, Japan²Department of Clinical Oncology, Aichi Cancer Center Hospital, Nagoya, Japan³Department of Gastroenterology and Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, Japan⁴Department of Immunology, Nagoya University Graduate School of Medicine, Aichi, Japan⁵Division of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, Japan⁶Division of Gastrointestinal Surgery, Kanagawa Cancer Center, Kanagawa, Japan⁷Division of Medical Oncology, Japanese Red Cross Ishinomaki Hospital, Miyagi, Japan⁸Department of Gastrointestinal Medical Oncology, National Cancer Center Hospital, Tokyo, Japan⁹Department of General Surgery, Kurashiki Central Hospital, Okayama, Japan¹⁰Department of Hematology/Oncology, Japan Community Healthcare Organization, Fukuoka, Japan¹¹Department of Gastrointestinal Surgery, Sendai City Medical Center, Sendai Open Hospital, Miyagi, Japan¹²Department of Gastroenterological Surgery, Gunma Prefectural Cancer Center, Gunma, Japan¹³Department of Gastroenterological Surgery, Japanese Red Cross Tokushima Hospital, Tokushima, Japan¹⁴Department of Cancer Multimodel Therapy Center, Kurume University Hospital, Fukuoka, Japan¹⁵Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan¹⁶Research and Development Center for Medical Education, Department of Clinical Skills Education, Kitasato University School of Medicine, Sagamihara, Japan¹⁷Department of Lower Gastrointestinal Surgery, Kitasato University School of Medicine, Sagamihara, Japan¹⁸Division of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan¹⁹Department of Surgery, National Hospital Organization Osaka National Hospital, Osaka, Japan²⁰Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Ltd, Tokyo, Japan²¹Department of Biostatistics, Yokohama City University School of Medicine, Yokohama, Japan²²Division of Molecular Diagnosis and Cancer Prevention, Saitama Cancer Center, Saitama, Japan²³Pathology Division, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan²⁴now with the Research Institute for Biomedical Sciences, Tokyo University of Science, Tokyo, Japan²⁵National Hospital Organization, Disaster Medical Center, Tokyo, Japan²⁶Division of Translational Informatics, Exploratory Oncology Research and Clinical Trial Center, National Cancer Center, Chiba, Japan

Nivolumab plus Ipilimumab in Microsatellite-Instability–High Metastatic Colorectal Cancer

Here is a large phase-III well done study confirming what we knew from earlier studies, that ipilimumab plus nivolumab (Ipi+Nivo) is highly active and effective in the microsatellite instability-high metastatic colorectal cancer (MSI-high met-CRC) population. This is most likely more effective than single agent IO therapy but with higher rates of toxicity. When all things are equal, I would consider this to be the standard of care (SOC) in this context.

Oxaliplatin Added to Fluoropyrimidine/Bevacizumab as Initial Therapy for Unresectable Metastatic Colorectal Cancer in Older Patients: A Multicenter, Randomized, Open-Label Phase III Trial (JCOG1018)

This Japanese study showed no benefit with the addition of oxaliplatin to fluoropyrimidine plus bevacizumab (5FU+bev) in patients who were aged 70-74 but unfit, or >=75. Interestingly survival was actually shorter in the patients who received oxaliplatin at 21.3 vs 19.7 months.

Lenvatinib Plus Pembrolizumab Versus Standard of Care for Previously Treated Metastatic Colorectal Cancer: Final Analysis of the Randomized, Open-Label, Phase III LEAP-017 Study

Overall survival (OS) improvement was not statistically significant in the study arm but is a non-chemotherapy option. Patients here had tumors with MSS.

Fluorouracil, Leucovorin, and Irinotecan Plus Cetuximab Versus Cetuximab as Maintenance Therapy in First-Line Therapy for RAS and BRAF Wild-Type Metastatic Colorectal Cancer: Phase III ERMES Study

Less maintenance is NOT NON-inferior, so it is inferior in patients with wild type BRAF metastatic colon cancer. So it is better to keep on the full regimen. Although, quality of life is better.

A Cell-free DNA Blood-Based Test for Colorectal Cancer Screening

Colorectal cancer screening by peripheral blood testing? This cell-free DNA assay had an 83% sensitivity and 90% specificity for advanced neoplasia. However, the issue is that this does not detect precancerous lesions well. Colonoscopy has its obvious advantages as it can both diagnose colorectal cancer as well as eradicate precancerous lesions.